Jemperli Side Effects

Generic name: dostarlimab

Medically reviewed by Drugs.com. Last updated on Apr 27, 2025.

Note: This document provides detailed information about Jemperli.

Applies to dostarlimab: intravenous solution Side Effects associated with dostarlimab. Some dosage forms listed on this page may not apply specifically to the brand name Jemperli.

Applies to dostarlimab: intravenous solution.

Precautions

It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly. Blood and urine tests may be needed to check for unwanted effects.

Receiving this medicine while you are pregnant can harm your unborn baby. If you are a woman who can bear children, your doctor may give you a pregnancy test before you start using this medicine to make sure you are not pregnant. Use an effective form of birth control to keep from getting pregnant during treatment with this medicine and for at least 4 months after the last dose. If you think you have become pregnant while receiving the medicine, tell your doctor right away.

Tell your doctor right away if you have a cough, chest tightness, or any type of breathing problem with this medicine. These could be symptoms of a serious lung problem.

Colitis (swelling of the colon or bowel) may occur with this medicine. Tell your doctor right away if you have stomach pain or tenderness, watery or bloody diarrhea, or a fever after receiving the medicine.

Check with your doctor right away if you have pain or tenderness in the upper stomach, pale stools, dark urine, loss of appetite, nausea, unusual tiredness or weakness, or yellow eyes or skin. These could be symptoms of a serious liver problem.

Serious problems with the adrenal, pituitary, or thyroid glands (hormone glands) may occur while you are receiving this medicine. Tell your doctor if you start having continuing or unusual headaches, changes in mood or behavior (eg, being irritable or forgetful), lightheadedness, dizziness, or fainting, unusual sluggishness, or an increase in weight.

This medicine may affect blood sugar levels. If you notice a change in the results of your blood or urine sugar tests or if you have any questions, check with your doctor.

This medicine may cause serious kidney problems (eg, nephritis, kidney failure). Tell your doctor right away if you have bloody or cloudy urine, nausea, vomiting, trouble breathing, swelling of the face, feet, or lower legs, unusual tiredness or weakness, or unusual weight gain.

Tell your doctor right away if you have changes in your eyesight, severe or persistent muscle or joint pain, or severe muscle weakness after receiving this medicine.

This medicine may increase your risk for possible organ transplant rejection. Talk to your doctor about this risk.

Serious skin reactions (eg, exfoliative dermatitis, Stevens-Johnson syndrome, drug rash with eosinophilia and systemic syndrome (DRESS), and toxic epidermal necrolysis) can occur with this medicine. Check with your doctor right away if you have blistering, peeling, or loosening of the skin, chills, cough, diarrhea, itching, joint or muscle pain, red irritated eyes, red skin lesions, often with a purple center, severe acne or skin rash, sores or ulcers on the skin, mouth or lips, or swollen glands, unusual bleeding or bruising, or unusual tiredness or weakness with this medicine.

This medicine may cause infusion-related reactions. These can be life-threatening and require immediate medical attention. Tell your doctor right away if you start to have a fever, chills or shaking, dizziness, trouble breathing, itching or rash, lightheadedness or fainting after receiving this medicine.

Serious side effects of Jemperli

Along with its needed effects, dostarlimab (the active ingredient contained in Jemperli) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking dostarlimab:

For healthcare professionals

Applies to dostarlimab: intravenous solution.

General adverse events

The most frequently observed adverse reactions (occurring in 20% or more) were fatigue/asthenia, anemia, rash, nausea, diarrhea, constipation, and vomiting.

The most common Grade 3 or 4 laboratory abnormalities (seen in 2% or more of patients) were decreased lymphocytes, decreased sodium, increased alanine aminotransferase, increased creatinine, decreased neutrophils, decreased albumin, and increased alkaline phosphatase.^[Ref]

Cardiovascular

• Uncommon (0.1% to 1%): Myocarditis^[Ref]

Dermatologic

• Very common (10% or more): Rash (rash, rash maculo-papular, rash pruritic, erythema, and pemphigoid; up to 21%), pruritus (up to 19%)^[Ref]

Endocrine

• Very common (10% or more): Hypothyroidism (up to 11%)
• Common (1% to 10%): Hyperthyroidism, adrenal insufficiency
• Uncommon (0.1% to 1%): Hypophysitis, thyroiditis^[Ref]

Gastrointestinal

• Very common (10% or more): Nausea (up to 32%), diarrhea (up to 29%), constipation (up to 23%), vomiting (up to 23%), abdominal pain (up to 15.1%)
• Common (1% to 10%): Colitis, pancreatitis, gastritis
• Uncommon (0.1% to 1%): Esophagitis
• Frequency not reported: Enterocolitis, hemorrhage, acute pancreatitis^[Ref]

Genitourinary

• Very common (10% or more): Urinary tract infection (up to 19%)^[Ref]

Hematologic

• Very common (10% or more): Anemia (anemia, decreased hemoglobin, iron deficiency, and iron deficiency anemia; up to 35%), decreased lymphocytes (up to 46%), decreased leukocytes (up to 21%), decreased neutrophils (up to 17%)
• Uncommon (0.1% to 1%): Autoimmune hemolytic anemia^[Ref]

Hepatic

• Very common (10% or more): Hypoalbuminemia (up to 36%), increased transaminases (increased alanine aminotransferase, increased aspartate aminotransferase, increased transaminases, and hypertransaminasemia; up to 13%), increased alkaline phosphatase (up to 31%), increased aspartate aminotransferase (up to 31%), increased alanine aminotransferase (up to 25%), increased total bilirubin (up to 7%)
• Uncommon (0.1% to 1%): Hepatitis
• Frequency not reported: Hepatocellular injury^[Ref]

Metabolic

• Very common (10% or more): Decreased appetite (up to 15%), hyponatremia (up to 29%), hypomagnesemia (up to 28%), hypokalemia (up to 22%), hypercalcemia (up to 8%), hyperkalemia (up to 14%)
• Common (1% to 10%): Hypermagnesemia, hypercalcemia
• Uncommon (0.1% to 1%): Type 1 diabetes mellitus, diabetic ketoacidosis^[Ref]

Musculoskeletal

• Very common (10% or more): Myalgia (up to 10%), arthralgia (up to 16.6%), back pain (up to 12.3%)
• Uncommon (0.1% to 1%): Immune-mediated arthritis, polymyalgia rheumatica, myositis^[Ref]

Nervous system

• Uncommon (0.1% to 1%): Myasthenia gravis, myasthenic syndrome, encephalitis^[Ref]

Ocular

• Uncommon (0.1% to 1%): Uveitis
• Frequency not reported: Iridocyclitis^[Ref]

Other

• Very common (10% or more): Fatigue (fatigue and asthenia; up to 49%), pyrexia (up to 13%)
• Common (1% to 10%): Chills, infusion-related reaction, sepsis
• Uncommon (0.1% to 1%): Systemic inflammatory response syndrome^[Ref]

Renal

• Very common (10% or more): Increased creatinine (up to 33%)
• Common (1% to 10%): Acute kidney injury
• Uncommon (0.1% to 1%): Nephritis
• Frequency not reported: Tubulointerstitial nephritis^[Ref]

Respiratory

• Very common (10% or more): Cough (up to 15%), dyspnea (up to 12.5%)
• Common (1% to 10%): Pneumonitis
• Frequency not reported: Interstitial lung disease^[Ref]

See also:

Further information

Jemperli side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer